Reports Library

New release!

European Biotech Industry Report 2021

european biotech industry report

The year 2020 was a rollercoaster ride for the life sciences. This report discusses how the Covid-19 pandemic has impacted Europe’s biotech and pharma industries and covers notable market trends, investments, fundraisings, mergers and acquisitions, and collaborations that occurred in 2020.

It also contains exclusive insights by leading industry experts and provides an overview of the European biotech startup landscape in 2020. Lastly, this report takes a look at how the biotech industry could evolve in 2021.

Download for free
(members only)
Buy now for €199
biotech reports

Explore more topics below 👇

The Genome Editing Toolbox: ZFNs, TALENs, and CRISPR in Biomedicine

While genome editing tools have been around for decades, most of the credit for this meteoric rise goes to CRISPR-Cas9. Its potential to change the lives of millions of patients around the world has piqued the interest of small and large biotechs as well as that of governmental and private investors.

This report covers the scientific background of the industry’s most common genome editing tools and provides exclusive industry insights by experts in the field. It also takes a look at the evolving genome editing market and addresses the future applications and challenges of genome editing tools.

A Guide to Current Therapies in Immuno-Oncology

immuno oncology report

Growing at a compound annual growth rate of 9,6%, the global immuno-oncology market is expected to reach a staggering value of $127B by 2026. What breakthroughs have led to these incredible developments and where are we going?

From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we take a look into its past, discuss present therapeutic approaches, and provide an outlook into its exciting future.

The Human Kinome: A Study of Protein Kinases

Kinome report

Dysregulation or mutations in kinases can result in numerous diseases. In fact, over 85% of the human kinome is involved in at least one disease or disorder, including cancer, cardiovascular disease, and neurological disorders.

Of over 500 kinases, only 80 have been targeted for the treatment of diseases so far. For drug developers, resistance and toxicity remain major challenges.

In this report, we study the science behind the human kinome, analyze the use of kinases as therapeutics, and discuss the exciting future of kinase inhibitors.

Peptides and Nucleic Acid Therapeutics: Dancing a Triumphant Tango

therapeutic peptides report

Increasing advances in genetics and bioengineering technologies have made gene therapy more accessible than ever before. The field of nucleic acid therapeutics, which is based on DNA, RNA, or closely related chemical compounds, is seen as promising for the treatment of genetic disorders and other diseases, including cancer, infectious, inflammatory, and neurodegenerative diseases.

In this report, we discuss the clinical potential of nucleic acid therapeutics and how they can be delivered safely to the region of interest. We will also take a look at the future of nucleic acid therapeutics and how related drug delivery systems will be advancing too.

Antibodies Through the Magnifying Glass: Their Past, Present and Future

Antibodies PDF report

One hundred thirty billion dollars – that’s the estimated worth of antibodies on the global market today. Compared to ten years ago, when global sales of antibodies reached $39B, this is an exciting leap. In fact, the market is also forecast to rise to a value of $224B by 2025.

This report will take you through the history of antibody discovery, study the science behind antibodies – their structure, types, and production, analyze the use of antibodies as therapies in immune-related disorders, cancer, and infectious diseases, and discuss the direction in which antibody research is going.

Beyond the Gut: An Atlas of the Human Microbiome

microbiome PDF report

Our entire body is made up of trillions of microorganisms – not only cells, as you may have believed. They even outnumber your cells ten to one. We call this flourishing flora of microorganisms the human microbiome. 

The microorganisms in our bodies are actually responsible for executing various bodily functions. But they can also cause disease. Here, we discuss how the gut and blood microbiomes play a role in different diseases, such as diabetes and inflammation, but also, how they can be used for biomarker discovery and the development of important therapeutics. 

A Toolkit for Emerging Biotechs: Practical Advice For Clinical Development

Toolkit for emerging biotech

Emerging biotechs are taking control of drug development pipelines. But as they become increasingly important players in the industry, leading innovation in the drug discovery and development space, competition grows too. 

In this report, we discuss the different challenges emerging biotechs face in the industry –  from surviving in a highly competitive environment to addressing funding issues, as well as the importance of defining and adhering to a strategy, working with the regulatory authorities, and the key points to look out for when searching for suitable collaborators. 

The Digital Transformation of the Research Lab: From Pen & Paper to Voice Recognition & AI

Lab automation report

In the US alone, more than $28B are lost annually on research that cannot be reproduced. Why? One reason is that many researchers still work with paper. But digitization, the process of turning paper-based information into a digital format, can make research more reproducible and efficient. In the long run, this saves money and time.

In this report, you will learn about the benefits of laboratory digitization, the limitations of electronic lab notebooks, and how AI and voice recognition will be the future of laboratory workflows.

Biotech Money Insider 2020: The Ultimate Guide To Biotech Investments in Europe

biotech investment 2020

Since 2018, we have published an annual insider view on the current European biotechnology industry. Each Biotech Money Insider presents you with an analysis of the most impactful investment trends, M&A deals, and IPOs of the previous year. 

In this e-book, you will learn about the funding trends in European biotech, explore the companies and countries that raised the largest amounts of money, discover the types of funds raised, and find out about the most influential investors in European biotech in 2019.

Buy now for €99

Biotech Money Insider 2019: The Ultimate Guide To Biotech Investments in Europe

Biotech Money Insider 2019

Since 2018, we have published an annual insider view on the current European biotechnology industry. Each Biotech Money Insider presents you with an analysis of the most impactful investment trends, M&A deals, and IPOs of the previous year. 

In this e-book, you will learn about the funding trends in European biotech, explore the companies and countries that raised the largest amounts of money, discover the types of funds raised, and find out about the most influential investors in European biotech in 2018.

Biotech Money Insider 2018: The Ultimate Guide To Biotech Investments in Europe

biotech investment report 2018

Since 2018, we have published an annual insider view on the current European biotechnology industry. Each Biotech Money Insider presents you with an analysis of the most impactful investment trends, M&A deals, and IPOs of the previous year. 

In this e-book, you will learn about the funding trends in European biotech, explore the companies and countries that raised the largest amounts of money, discover the types of funds raised, and find out about the most influential investors in European biotech in 2017.